Margaret Horn - Aug 31, 2023 Form 4 Insider Report for Revolution Medicines, Inc. (RVMD)

Signature
/s/ Jack Anders, as Attorney-in-fact for Margaret Horn
Stock symbol
RVMD
Transactions as of
Aug 31, 2023
Transactions value $
-$299,558
Form type
4
Date filed
9/1/2023, 04:16 PM
Previous filing
Aug 17, 2023
Next filing
Sep 19, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RVMD Common Stock Options Exercise $40.9K +10K +10.05% $4.09* 109K Aug 31, 2023 Direct F1, F2
transaction RVMD Common Stock Sale -$340K -10K -9.13% $34.05 99.5K Aug 31, 2023 Direct F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RVMD Stock Option (Right to Buy) Options Exercise $0 -10K -8.45% $0.00 108K Aug 31, 2023 Common Stock 10K $4.09 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 29, 2023.
F2 Includes 70,738 restricted stock units.
F3 This transaction was executed in multiple trades in prices ranging from $34.00 to $34.08, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.